National Institute of Allergy and Infectious Diseases
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

Radiation Countermeasures
 Program
 Research Areas
 Resources
 Funding
 Summaries and Publications
 Congressional Testimonies


Medical Countermeasures Against Radiological and Nuclear Threats

Meetings and Training

Future Meetings

Past Meetings

Training

back to top

Highlights

RFA-09-036: Centers for Medical Countermeasures Against Radiation (U19)

RFP-NIAID-DAIT-NIHAI2009079: Radiation/Nuclear Medical Countermeasure Product Development Support Services

BAA-NIAID-DAIT-NIHAI2009051: Development of Oral Radionuclide Decorporation Agents for Use in Radionuclide Decorporation in Radiological Emergencies

BAA-NIAID-DAIT-NIHAI2009060: Development of Oral Form of Diethylenetriaminepentaacetate (DTPA) for Use in Radionuclide Decorporation – Radiological Emergency 

PA-09-093: Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44]).  Standard SBIR receipt dates.

Solicitation: BAA-BARDA-09-34: BARDA Broad Agency Announcement for the Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures

See Also

  • Radiological and Nuclear Threats News Releases
  • Division of Allergy, Immunology, and Transplantation (DAIT)
  • Biodefense—The NIAID Biodefense Web site includes biodefense-related information for biomedical researchers, the public, and the media.

  • Highlights

    RFA-09-036: Centers for Medical Countermeasures Against Radiation (U19)

    RFP-NIAID-DAIT-NIHAI2009079: Radiation/Nuclear Medical Countermeasure Product Development Support Services

    BAA-NIAID-DAIT-NIHAI2009051: Development of Oral Radionuclide Decorporation Agents for Use in Radionuclide Decorporation in Radiological Emergencies

    BAA-NIAID-DAIT-NIHAI2009060: Development of Oral Form of Diethylenetriaminepentaacetate (DTPA) for Use in Radionuclide Decorporation – Radiological Emergency 

    PA-09-093: Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44]).  Standard SBIR receipt dates.

    Solicitation: BAA-BARDA-09-34: BARDA Broad Agency Announcement for the Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures

    See Also

  • Radiological and Nuclear Threats News Releases
  • Division of Allergy, Immunology, and Transplantation (DAIT)
  • Biodefense—The NIAID Biodefense Web site includes biodefense-related information for biomedical researchers, the public, and the media.